BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellectricon AB Signs Collaboration Agreement With AstraZeneca PLC (AZN)


5/3/2006 10:38:03 AM

GOTHENBURG, Sweden, May 3 /PRNewswire/ -- Cellectricon, a leading provider of microfluidic & cell-based tools to improve and accelerate drug discovery, today announced collaboration with AstraZeneca, under which the companies will study the possibility of developing a new cell-based microfluidic screening platform. The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.

"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery," says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."

"We believe the Nanoflow system has the potential to expedite our efforts in ion channel drug discovery and we look forward to working in collaboration with Cellectricon," says Dr. Christer Nordstedt, VP Discovery Research Area CNS & Pain Control.

About Cellectricon

Cellectricon invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products are designed to enable substantial increases in productivity at the highest data quality. The company currently offers two products for the life science market:

Dynaflow(TM) - Screening and lead optimization for drugs acting on ion channel receptors and safety pharmacology testing.

Cellaxess(TM) - Screening and transfection tool for cell-based assays in the fields of intracellular targets and RNA interference.

Cellectricon AB

CONTACT: Contact Details: Susanne Fagerlund, Communications Manager,Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES